US Denosumab Race Remains Busy As Amneal And mAbxience See Filing Accepted
Celltrion Just Became Third Firm To Win US Denosumab Approval; Many Other Chasers
Ahead of the first biosimilars to denosumab emerging later in the spring, the market is continuing to prove enticing, with Amneal the latest to file for biosimilars to Prolia and Xgeva.
